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Abstract
Background: We aimed to validate prognostic scores for survival in patients undergoing chemotherapy for
advanced or metastatic cancer after first-line treatment.
Methods: We previously described two models with good prognostic value based on a combination of
Performance Status (PS) and either lactate dehydrogenase (LDH) level or lymphocyte count. These factors were
evaluated for their ability to predict overall survival (OS) in a prospective cohort of 299 patients. Clinical and blood
parameters were prospectively recorded. Candidate prognostic factors for OS with 0.05 significance level in
univariate analysis were included in a multivariate Cox model.
Results: Median age was 59 years (range: 26-85). Primary tumor sites were breast (45%), lung (15%), ovaries (11%)
and others (29%). The number of metastatic sites was 1 (29%), 2 (48%), >2 (23%). Median follow-up and median OS
were 12 and 6 months, respectively. Multiple regression analysis confirmed that PS >1, lymphocyte count ≤700/μL
and LDH >600 UI/L were independent predictors of short OS, as well as interleukin 6 (IL-6) level, serum albumin
concentration and platelet count.
Conclusions: Prognostic scores using PS plus LDH level or PS plus lymphocyte count were validated for predicting
survival in metastatic cancer patients in relapse beyond first-line treatment. A score combining PS, LDH,
lymphocyte and platelet count, serum albumin and IL-6 level was superior in determining patients’ prognosis.
Background
Prediction of survival for patients with advanced cancer
who have already received first-line treatment is critical to
decision making regarding subsequent treatments. Models
allowing accurate estimation of life expectancy are needed
to make a more informed treatment decision, in particular
to guide decisions about chemotherapy in vulnerable
patients. Doctors’ survival predictions for palliative
patients are often optimistic [1,2]. The Research Network
of the European Association for Palliative Care (EAPC)
has provided evidence-based clinical recommendations for
prognosis in patients with advanced cancer [3]. One of the
six key recommendations is that physicians should system-
atically use prognostic scores to stratify patients into
groups with different survival times. One of the prognostic
tools specifically considered by the working group was the
Palliative Prognostic (PaP)score based on Performance
Status (PS), the presence or absence of dyspnea and anor-
exia, white blood cell counts, and the clinician’s prediction
of survival. It has been validated successfully in patients
admitted to the oncology ward of a university teaching
hospital [4]. However, the PaP score may be limited in
that it was developed in the 1990 s for patients with far-
advanced cancer referred to community hospitals.
We aimed to develop a novel prognostic scoring sys-
tem for patients undergoing chemotherapy. Predictive
models for survival integrating combinations of clinical
and biological factors have been reported [5-10]. Biolo-
gical characteristics such as lactate dehydrogenase
(LDH) level [6], lymphocyte count [5,7], interleukin 6
(IL-6) level [8,9], or vascular endothelial growth factor
(VEGF) level [10] have been correlated with poor out-
come. The primary endpoint of this study was the vali-
dation of two prognostic scores that we have previously
shown to be correlated with survival in a Cox propor-
tional hazards regression model. These scores were
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based on PS plus LDH level (score A) or PS plus lym-
phocyte count (score B). Both scores have been shown
to stratify patients into groups with significantly differ-
ent survival prognosis [6,7]. We also aimed to investi-
gate a third model including additional clinical and
biological characteristics and thus potentially allowing
for more accurate prognostication.
Methods
This was a prospective, observational, single-centre
study.
Patients
Inclusion criteria were: patients >18 years old with
locally advanced or metastatic cancer who had received
at least one line of systemic treatment (chemotherapy or
immunotherapy) for metastatic disease. Enrolment was
proposed after failure of the line of treatment being
administered, when decision was made to shift to a dif-
ferent treatment. Patients were excluded from the study
if they were not covered by the French health insurance
system. Written informed consent was obtained from
each patient. The institutional ethics committee (named
CCPPRB Lyon-B) approved the study protocol before
implementation, on March 17, 2000.
Data
The case report form of the study was designed to collect
the following parameters: age, gender, Eastern Cooperative
Oncology Group (ECOG) PS, weight loss (> 10% of the
initial body weight in the 6 months before study inclu-
sion), primary diagnosis, number and sites of metastases,
previous and current anticancer treatments, interval
between diagnosis, first recurrence and study inclusion,
and quality of life (QoL) assessed by the patients them-
selves on a 0-10 visual analog scale (VAS). Laboratory
tests included complete blood counts (hemoglobin,
neutrophils, lymphocytes, platelets), albumin, LDH and
C-reactive protein (CRP) levels. Serum samples were col-
lected and stored at -80°C. Commercially available immu-
noassay kits were used according to the manufacturers’
instructions in order to determine IL-6 and Vascular
Endothelial Growth Factor (VEGF) levels [8,9]. According
to our previous studies [6-10], the cutoff of each para-
meter was albumin: 38 g/L, lymphocytes: 700 μL-1, LDH:
600 U/L, IL-6: 8 pg/mL, and VEGF: 755 pg/mL. As for
CRP, several studies in different cancer sites have demon-




In retrospective cohorts from our institution, 20% of
metastatic cancer patients died within three months
after the beginning of the chemotherapy. With 300
patients enrolled, we expected to have a 73% power to
detect a hazard ratio of 1.5 in the final model [14].
Survival analysis
the primary outcome was overall survival, defined as the
time from inclusion to date of death or date of last fol-
low-up for patients alive at last contact. Survival distri-
butions in prognostic groups were estimated by the
Kaplan-Meier method.
Univariate and multivariate analyses
to evaluate the relationship between survival and base-
line characteristics, all clinical and biological variables
were included in univariate Cox proportional hazard
regression models. For validation of scores A and B,
parameters from each score were entered in multivariate
Cox models. Furthermore, candidate prognostic factors
for OS with a 0.05 level of significance in univariate
analysis were entered in a multivariate Cox model.
A backward selection procedure was then used to build
a third model. All relevant interactions were included in
the model and then non-significant ones were removed
step by step to obtain the final model. Based on the
final Cox proportional hazard model, a prognostic score
was computed for each patient. It consisted in the sum
of the baseline variables multiplied by the estimated
coefficients for these baseline variables. Participants
were grouped in quantiles of the prognostic score corre-
sponding to quantiles of risk. Overall survival curves
were then plotted depending on the quantile of risk.
Quantification of the performance of each score
to test whether the addition of parameters significantly
improves the goodness of fit, comparisons between
scores were performed using a likelihood ratio test
(LRT). This test applies to nested models and is based
on the LRT statistic calculated from the likelihood
scores of the two models to be compared. The LRT sta-
tistic follows a chi-square distribution, with degrees of
freedom equal to the number of additional parameters
in the most complex model. Lower likelihood scores
indicate a better fitted model. In addition, similarly to
the report by Chow et al [15], the C index proposed by
Harrell et al [16] and the D-statistic of Royston and
Sauerbrei [17] were calculated for the 3 models as mea-
sures of discrimination. The C index is the probability
that, for a randomly chosen pair of patients, the pre-
dicted and observed outcomes are concordant (i.e. the
patient having the best outcome is the one having the
best predicted outcome). A value of 0.5 indicates no
predictive discrimination and a value of 1.0 indicates
perfect separation of patients with different outcomes.
We also calculated a C index corrected for possible
overfitting using the bootstrap method, which is the
bias-corrected C index [16]. This index is a better esti-
mate of how well the model will discriminate prognosis
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in the future. The D-statistic was also used as a measure
of discrimination of the survival models because of its
ability to stratify the risk of death among groups of
patients. The larger the D statistic, the greater the
degree of separation in a prognostic model.




Between 2000 and 2005, 300 patients treated in our
institution (Léon Bérard Comprehensive Cancer Centre,
Lyon, France) for locally advanced or metastatic cancer
and who had failed first-line treatment were enrolled in
the study. In our institution, most patients receive more
than two lines of chemotherapy, which is covered by the
French public health insurance system. One patient was
excluded from the analysis because he was enrolled
before first-line chemotherapy.
The characteristics of the 299 patients analyzed are
summarized in Table 1. Two hundred and twenty
patients (74%) were female. Median age was 58.6 years
(range 26-85). Many patients (132 of 299; 45%) pre-
sented with metastatic breast cancer; 132 (44%) had PS
> 1. Only 47 patients (16%) suffered from locally
advanced cancer without metastasis. Sixty-three (22%)
patients had presented with a weight loss of 10% or
more in the previous 6 months. On a 0 to 10 scale
(VAS), the median QoL score as self-assessed by the
patients was 5 (range: 0-10); 25% of the patients pre-
sented with VAS <3.5. The median time intervals
between initial diagnosis and inclusion, and between
first recurrence and inclusion were 39 months (range:
0.8-472 months) and 17 months (range: 0-148 months),
respectively.
Biological variables are shown in Table 2. Complete
blood count was available for 295 patients (99%). Other
laboratory data were missing due to incomplete collec-
tion of blood samples by the referring physicians.
A majority of patients presented with anemia (58%), low
serum albumin (70%), elevated CRP (> 10 mg/L; 59%).
Ninety-six (32%) patients had lymphopenia ≤700/μL and
32 (11%) had thrombopenia ≤130 G/L. The median time
interval between the last chemotherapy and study inclu-
sion was 1.1 month, both for the entire cohort and for
patients with lymphopenia ≤700/μL. Respectively 130
(48%) and 66 (24%) patients had IL-6 >8 pg/mL and
VEGF >755 pg/mL.
Survival
The median follow-up was 11.9 months. Two hundred
and sixty-four patients (89%) were dead at the date
of evaluation. Median OS was 6.4 months (95% CI,
5.6-7.2).
Validation of the two pre-existing prognostic scores
The prognostic value for overall survival of score A,
with PS >1 (HR = 2.52 [95% CI, 1.87-3.40]) and LDH
>600 U/L (HR = 1.80 [95% CI, 1.34-2.42]), and score B,
with PS >1 (HR = 2.80 [95% CI, 2.13-3.68]) and
Table 1 Patient characteristics
Patient Characteristics Number (Percentage)
Total 299 (100)
Age (years)







> 1 132 (44)






Head and neck 18 (6)
Colorectal 12 (4)
Soft tissue 11 (4)
Other 47 (16)
Number of metastatic sites
1 86 (29)
2 139 (46)









Adjuvant chemotherapy 119 (42)
Immunotherapy 29 (10)








Radiation therapy 3 (1)†
Supportive care 4 (1)
† patients may have received combination therapies.
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lymphocytes ≤700/μL (HR = 1.69 [95% CI, 1.30-2.20]),
was validated in the study cohort (Figure 1A and 1B).
Scores A and B were validated for the most common
types of primary tumors (Figure 2A and 2B).
Building of a more accurate prognostic score
In univariate analysis, 12 of 16 variables were found to
be significant at a 5% level (Table 3). In multivariate
analysis (209 patients), 6 variables were associated with
a significantly poorer prognosis: PS >1, IL-6 >8 pg/mL,
LDH >600 U/L, lymphocytes ≤700/μL, albumin < 38 g/L
and platelets < 130 G/L (Table 4). Only PS >1 was asso-
ciated with a more than two-fold increased hazard ratio
of death. Interactions between type of cancer and each
of the 5 significant variables were tested in the multi-
variate model using a backward selection procedure: no
interaction was found to be significant in the final
model. Interestingly, a forward selection has been also
applied to the data, resulting in the same final model.
According to the quantiles of risk based on the final
cox proportional hazrard model, low risk (≤ 2.5; 31%),
medium risk (between 2.5 and 5; 35%) and high risk (>
5; 34%) were associated with median OS of 18, 5 and
4 months, respectively. The different survival curves are
shown in Figure 1C.
Focusing on breast cancer patients (Table 5), 3 prog-
nostic factors remained independently predictive of
overall survival: PS >1 (HR = 2.08 [95% CI, 1.30-3.35]),
LDH >600 U/L (HR = 2.47 [95% CI, 1.56-3.92]) and IL-
6 >8 pg/mL (HR = 1.83 [95% CI, 1.17-2.86]).
Quantification of score performance
Results of the LRT when scores A and B were tested in
the current cohort were 2002 and 2425, respectively.
The D statistics were 0.93 and 0.97 and the C indexes
0.66 [95% CI, 0.63-0.69] and 0.67 [95% CI, 0.64-0.70] for
scores A and B, respectively.
Using the new prognostic score combining the 6 sig-
nificant variables (PS, LDH, lymphocytes, IL-6, albumin
and platelets), the LRT was 1577, which is better than
with either score A or B (p < 0.0001). Similarly, the D
statistic was 1.23, which is in favour of a better predic-
tive discrimination than with either score A or B. The C
index was 0.72 [95% CI, 0.68-0.76], which indicated
good concordance between predicted and observed
values. Furthermore, the bias-corrected C index
obtained from 1000 bootstrap samples was 0.71.
Discussion
In this prospective study, both score A (PS plus LDH
level) and score B (PS plus lymphocyte count) were vali-
dated as suitable for identifying distinct risk groups with
different durations of survival. Furthermore, we showed
that the combination of PS and biological covariates
such as LDH, lymphocyte and platelet counts, serum
albumin and IL-6 levels is an effective strategy to predict
survival for patients with advanced or metastatic cancer
receiving further treatment after the first-line. Our third
model including all six parameters was successfully vali-
dated according to the different methods used. Notably,
the bias-corrected C index that was used as an alterna-
tive for external validation confirmed the good perfor-
mance of the model. However, this validation study has
several limitations. The percentage of colorectal cancer
patients in our population study is low (3.7%), which









< 2000/μL 16 (5)
2000-7500/μL 225 (76)








< 130 G/L 32 (11)
130-400 G/L 231 (78)
> 400 G/L 32 (11)
Missing data 4
Albumin
< 38 g/L 172 (70)
Missing data 52
LDH
> 600 U/L 89 (36)
Missing data 48
CRP
≤10 mg/L 92 (41)
10-50 mg/L 79 (35)
> 50 mg/L 54 (24)
Missing data 74
IL-6
> 8 pg/mL 133 (48)
Missing data 21
VEGF
> 755 pg/mL 66 (24)
Missing data 20
LDH: lactate dehydrogenase; CRP: C-reactive protein; IL-6: interleukin 6; VEGF:
Vascular Endothelial Growth Factor.
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Figure 1 Analysis of quantiles of the prognostic score corresponding to quantiles of risk with Kaplan-Meier overall survival analysis
and Cox proportional hazard regression model, using score A with ECOG performance status and lactate dehydrogenase level (Figure
1A), score B with ECOG performance status and lymphocyte count (Figure 1B), or ECOG performance status, lactate dehydrogenase
level, lymphocyte count, serum albumin and platelet count (Figure 1C). Participants with risk >5 were pooled. No participant was in this
group with score A or B.
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may represent a selection bias. Also, there are several
missing biochemical parameters, especially CRP (25%).
Furthermore, regarding the CRP cutoff, we have tested
it at 10 mg/L, which may appear to be low for advanced
cancer patients, and may explain why CRP was not
statistically significant in our multivariate analysis. How-
ever, several studies have already reported data on can-
cer patients with this cutoff [11-13].
The decision to stop chemotherapy is one of the hard-
est challenges in oncology practice. Chemotherapy
OTHER (n = 56)
OVARY (n = 31)
LUNG (n = 30)
BREAST (n = 101)












OTHER (n = 86)
OVARY (n = 34)*
LUNG (n = 45)
BREAST (n = 131)








* No graphic representation for ovary patients because only one patient is considered at risk with score A
Figure 2 Results of Cox proportional hazard regression model in the most common types of primary tumors, using score A with
ECOG performance status and lactate dehydrogenase level (Figure 2A), and score B with ECOG performance status and lymphocyte
count (Figure 2B).
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remains widely prescribed for terminally ill patients
despite side effects and poor efficacy [18,19]. We aimed
to develop prognostic scores that would help clinicians
estimate patients’ survival regardless of initial tumor
site. Therefore, we validated our prognostic scores in
different cancer patient populations (Figure 2A and 2B).
We acknowledge that, although cancer treatment is
known to be cancer-type dependent, we did not include
in our analysis prognostic factors specific to each cancer
type. However, our scores are of importance and of
potential clinical relevance since they may help the phy-
sicians discuss palliative treatment options with the
patients and their families. Prognostication is not simply
prediction of response to therapy, and some prognostic
factors, such as PS or lymphocyte count, are useful
across different tumor types, as we and others have
already shown [4,10,15,20,21]. Furthermore, clinical or
pathological data such as tumor grade or node involve-
ment can reasonably be used as prognostic factors in
early-stage disease. After first-line treatment failure,
these data do not seem suitable for predicting short-
term prognosis [22,23].
Several clinical signs have been shown to be prognos-
tically important in terminally ill cancer patients. For
Table 3 Prognostic parameters on univariate analysis
Univariate analysis
HR 95% CI p value
ECOG Performance Status
0-1
> 1 2.95 [2.27-3.84] < .0001
Platelet count (G/L)
≥130
< 130 2.67 [1.83-3.88] < .0001
CRP (mg/L)
≤10
> 10 2.25 [1.67-3.04] < .0001
LDH (U/L)
≤600
> 600 2.17 [1.64-2.88] < .0001
IL-6 (pg/mL)
≤8
> 8 2.16 [1.66-2.81] < .0001
Albumin (g/L)
≥38
< 38 2.12 [1.56-2.89] < .0001
Hemoglobin
Normal
Abnormal† 1.88 [1.46-2.43] < .0001
Weight loss >10% (in the past 6 months)
No
Yes 1.83 [1.37-2.45] < .0001
Lymphocyte count
> 700/μL
≤700/μL 1.80 [1.39-2.33] < .0001
VEGF (pg/mL)
≤755
> 755 1.55 [1.15-2.09] 0.0044
Number of metastatic sites
≤2
> 2 1.50 [1.14-1.99] 0.0042
Quality of life using 0-10 VAS
≥5
< 5 1.53 [1.18-1.98] 0.0012
Absolute neutrophil count
≥2
< 2 1.30 [0.78-2.16] 0.3
Liver metastases
No
Yes 1.19 [0.93-1.53] 0.16
Age (years)
≤60
> 60 0.97 [0.76-1.23] 0.8
Previous adjuvant chemotherapy
No
Yes 0.91 [0.71-1.18] 0.5
Table 4 Prognostic parameters on multivariate analysis
(209 patients)
Multivariate analysis
HR 95% CI p value
ECOG Performance Status
0-1
> 1 2.07 [1.48-2.91] < 0.0001
IL-6 (pg/mL)
≤8
> 8 1.72 [1.25-2.36] 0.0009
LDH (U/L)
≤600
> 600 1.60 [1.16-2.21] 0.0045
Lymphocyte Count
> 700/μL
≤700/μL 1.43 [1.04-1.95] 0.0268
Albumin (g/L)
≥38
< 38 1.47 [1.02-2.11] 0.0374
Platelet count (G/L)
≥130
< 130 1.70 [1.02-2.81] 0.0402
LDH: lactate dehydrogenase; IL-6: interleukin 6.
LDH: lactate dehydrogenase; CRP: C-reactive protein; IL-6: interleukin 6; VEGF:
Vascular Endothelial Growth Factor; VAS: visual analog scale.
† < 11.5 g/dL for women, <13.0 g/dL for men.
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example, dyspnea, constipation, dizziness, pain, anxiety
or depression are individually related to life expectancy,
but their prognostic value has rarely been confirmed in
multivariate analyses [20,24,25]. Therefore, our group
developed 2 different PS-based prognostic scores using
unbiased biological variables (scores A and B). Score B,
described by Ray-Coquard et al [7], uses lymphopenia
as a predictor of early death after chemotherapy. The
threshold level of 700 lymphocytes per μl was chosen
because it predicts hematological toxicity in patients
who receive chemotherapy, as demonstrated in previous
studies [5,7,26,27]. We recently showed that lymphope-
nia, with a lymphocyte count of <1000/μl, is also an
independent prognostic factor for overall and progres-
sion-free survival in several cancers [21]. Score A was
published by Bachelot et al [6]. Their study included
154 patients with solid tumors enrolled in phase I clini-
cal trials. PS >1 and high serum LDH level (> 600 U/L)
were identified as independent prognostic factors for
OS. Several studies have shown that elevated LDH is
significantly associated with survival in patients with
terminal cancer [28-31]. Bozcuk et al and Suh et al have
set the threshold for high LDH level at 378 U/L and 313
U/L, respectively [29,31]. However, reasons for patient
admission in Bozcuk’s study included life-threatening
situations, whereas Suh’s study included only patients
who had been admitted to the palliative care unit.
Most studies show that PS (assessed by the Karnofsky
Performance Scale or by the ECOG scale) correlates
with duration of survival [3,6,7,20,24,25]. Recently, Kiku-
chi et al. have shown the benefit of adding biological
markers such as serum albumin, LDH level, platelet and
lymphocyte count to predict survival in terminally-ill
cancer patients [32]. Serum albumin concentration is a
well-known independent predictor of mortality risk [33].
In the current study, we also confirmed the prognostic
value of the pro-inflammatory cytokine IL-6 [8,9,34].
However, IL-6 level is not clinically available and the
usefulness of routine IL-6 assessment should be further
investigated. Also, in our study we decided to use
dichotomous variables that make clinical interpretation
easier (the risk is either present or absent). However, we
acknowledge that strong prognostic marker could be
better included as linear parameter to take advantage of
its prognostic information over the whole range of
potential cutoffs. This might have enabled the calcula-
tion of a potentially more powerful prognostic
algorithm.
Conclusions
In conclusion, we have validated two prognostic scores
(score A: PS plus LDH level, and score B: PS plus lym-
phocyte count) and confirmed that combination of PS
and biological covariates such as serum albumin con-
centration, LDH level, lymphocyte count, thrombocyto-
penia and IL-6 level is an effective strategy to predict
survival for patients with advanced or metastatic cancer
receiving further treatment after first-line failure.
Because prediction of survival is variable among physi-
cians, adding more objective measures would improve
the accuracy of the score and facilitate treatment deci-
sion making in metastatic cancer patients, regardless of
initial tumor site.
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